Hematology-American Society of Hematology Education Program

Article	Citations
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	43
Clots in unusual places: lots of stress, limited data, critical decisions	40
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	34
Acute GVHD: think before you treat	27
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	26
Optimal approach to T-cell ALL	26
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy	24
The dos, don'ts, and nuances of thrombophilia testing	23
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	22
Controversies in the management of early-stage Hodgkin lymphoma	22
Mastocytosis demystified	22
Diagnosis and therapeutic decision-making for the neutropenic patient	21
Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia	21
Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML	20
Inpatient recognition and management of HLH	20
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients	20
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	18
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	18
Lifelong TKI therapy: how to manage cardiovascular and other risks	17
What factors guide treatment selection in mycosis fungoides and Sezary syndrome?	17
AL amyloidosis: untangling new therapies	17
Dual-targeted regimens for the frontline treatment of CLL	17
Relapsed ALL: CAR T vs transplant vs novel therapies	16
Diagnostic pitfalls and conundrums in type 1 von Willebrand disease	16
Labor and delivery: DIC, HELLP, preeclampsia	16

Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	16
Bispecific antibody therapies	15
Cytoreduction for ET and PV: who, what, when, and how?	15
Provoked vs minimally provoked vs unprovoked VTE: does it matter?	15
How do we optimally utilize factor concentrates in persons with hemophilia?	14
Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?	13
Thrombocytopenia in pregnancy	13
What have we learned about the patient's experience of von Willebrand disease? A focus on women	13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	13
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies	13
Novel immunotherapies in the treatment of AML: is there hope?	13
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	12
Management of Fanconi anemia beyond childhood	12
Novel platelet products including cold-stored platelets	12
Biology of follicular lymphoma: insights and windows of clinical opportunity	12
Modern management of Fanconi anemia	12
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	11
Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2021;2021:521-528.	11
Recognizing, defining, and managing CAR-T hematologic toxicities	11
Dyskeratosis congenita and telomere biology disorders	11
Gene therapy for hemophilia	11
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	10
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	10
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	10
On the horizon: upcoming new agents for the management of ITP	10
Neurological manifestations of MGUS	10
Novel conditioning and prophylaxis regimens for relapse prevention	10
Mutations and MRD: clinical implications of clonal ontogeny	10
The POD24 challenge: where do we go from here for early progressors?	10
New definitions for antiphospholipid syndrome: ready for clinical use?	10
Your chemo is no good here: management of high-risk MCL	10
Treatment of VTE in the thrombocytopenic cancer patient	10
What makes a pediatric or young adult patient an appropriate transplant candidate?	9
Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation	9
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	9
Pegylated interferon: the who, why, and how	9
Modified T cells as therapeutic agents	9
Anticoagulation at the end of life: whether, when, and how to treat	9
Risk-stratification in frontline CLL therapy: standard of care	9
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	8
Using disease-modifying therapies in sickle cell disease	8
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	8
Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy	8
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?	8
Platelet components and bacterial contamination: hospital perspective 2022	8
Options at the time of relapse after anti-BCMA therapy	8
Novel approaches to acute graft-versus-host disease prevention	7
Upfront therapy: the case for continuous treatment	7
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	7
Passive immune therapies: another tool against COVID-19	7

What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	7
Pyruvate kinase activators for treatment of pyruvate kinase deficiency	7
Amyloid consults do not have to be vexing	7
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma	7
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	7
Heparin-induced thrombocytopenia and cardiovascular surgery	7
Long-term health outcomes following curative therapies for sickle cell disease	7
T-cell lymphopenia in frequent volunteer platelet donors	7
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	7
How to avoid early mortality in acute promyelocytic leukemia	7
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy	7
Identifying and treating iron deficiency anemia in pregnancy	7
Next-generation therapy for lower-risk MDS	7
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure	7
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	7
Molecular prognostication in Ph-negative MPNs in 2022	6
Multiple myeloma: a paradigm for blending community and academic care	6
Williams KM. Noninfectious complications of hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2021;2021:578-586.	6
Givosiran: a targeted treatment for acute intermittent porphyria	6
What is the ideal approach—doublet, triplet, or quadruplet(s)?	6
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	6
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	6
Have we reached a molecular era in myelodysplastic syndromes?	6
Clinical manifestations of telomere biology disorders in adults	6
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	6
Targeted medical therapies for vascular anomalies	6
Has PD-1 blockade changed the standard of care for cHL?	6
Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia	6
Evidence-based management of pregnant women with sickle cell disease in high-income countries	6
Cold AIHA and the best treatment strategies	6
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	6
Challenges in hospice and end-of-life care in the transfusion-dependent patient	6
In pursuit of a functional cure for follicular lymphoma	6
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	5
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	5
Perioperative consultative hematology: can you clear my patient for a procedure?	5
Optimal approach to T-cell ALL	5
Diagnosis and laboratory monitoring of acquired hemophilia A	5
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	5
Biology of post-transplant relapse: actionable features	5
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	5
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	5
Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?	5
Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?	5
Updates on strategies to integrate palliative care in hematologic malignancy	5
Ph− ALL: immunotherapy in upfront treatment	5
Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations	5
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	5
Resistance mutations in CML and how we approach them	5
New investigational combinations for higher-risk MDS	5
Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?	5
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy	5
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	5
Transplant in myeloma: who, when, and why?	4
Should we use bisphosphonates to treat bone complications in sickle cell disease?	4
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	4
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL	4
Newborn screening initiatives for sickle cell disease in Africa	4
Troubleshooting heparin resistance	4
The first relapse in multiple myeloma: how to pick the next best thing	4
Allogeneic transplantation for advanced acute leukemia	4
Whom should we treat with novel agents? Specific indications for specific and challenging populations	4
Sequencing bispecific antibodies and CAR T cells for FL	4
The role of stem cell transplant (auto and allo) in PTCL and CTCL	4
Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease	4
BV and beyond: how to incorporate novel agents into PTCL management	4
MGCS: where do we stand today?	4
New approaches to tackle cytopenic myelofibrosis	4
Divergent paths: management of early relapsed follicular lymphoma	4
Renal manifestations of MGUS	4
The intersection of sickle cell disease, stigma, and pain in Africa	4
IgG4-related disease for the hematologist	4
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	4
Supportive care in myeloma—when treating the clone alone is not enough	4
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	4
Evidence-based obstetric management of women with sickle cell disease in low-income countries	4
Current use of CAR T cells to treat multiple myeloma	4
When to use stem cell transplantation for classical Hodgkin lymphoma	4
Medical consult: aHUS, TTP? How to distinguish and what to do	3
Advances in the management of α-thalassemia major: reasons to be optimistic	3

Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?	3
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	3
Management of aggressive lymphoma after CAR T-cell therapy failure	3
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	3
Treatment of Richter's syndrome	3
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	3
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	3
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too	3
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	3
Selecting initial therapy in CLL	3
Pyruvate kinase activators: targeting red cell metabolism in thalassemia	3
Diagnosis and clinical management of red cell membrane disorders	3
Achieving MRD negativity in AML: how important is this and how do we get there?	3
Approaches to optimize outcomes in transplant recipients	3
Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?	3
Novel therapies upon failure of HMA plus venetoclax	3
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	3
Inflamed—HLH, MAS, or something else?	3
When to consider inherited marrow failure syndromes in adults	3
Fitness and frailty in myeloma	3
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	3
How to assess hemostasis in patients with severe liver disease	3
Does MRD have a role in the management of iNHL?	2
Managing side effects: guidance for use of immunotherapies in multiple myeloma	2
Prevention, diagnosis, and management of PE and DVT in pregnant women	2
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	2
Frontline treatment in CLL: the case for time-limited treatment	2
Approach to the patient with suspected hypereosinophilic syndrome	2
Allogeneic hematopoietic cell transplantation for older patients	2
How to manage hemostasis in patients with liver disease during interventions	2
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	2
COVID-19 and thrombosis: searching for evidence	2
Mutational screening to improve the transplantation decision-making process in MDS	2
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond	2
Transplant for TP53-mutated MDS and AML: because we can or because we should?	2
Incorporating gonadal health counseling into pediatric care of sickle cell patients	2
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	2
Risk factors and screening for neurocognitive impacts of therapy	2
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?	2
Gene therapy for sickle cell disease	2
Optimizing outcomes in secondary AML	2
Clonal evolution in inherited marrow failure syndromes predicts disease progression	2
How to recognize and manage COVID-19-associated coagulopathy	2
What else do I need to worry about when treating graft-versus-host disease?	2
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	2
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	2
The burden of myeloma: novel approaches to disease assessment	2
Blast and accelerated phase CML: room for improvement	2
Newly diagnosed multiple myeloma: making sense of the menu	2